Healthcare Business Report: Regeneron’s Upbeat Eylea Survey, Humana’s Win In Kentucky

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Xoma (NASDAQ:XOMA) reports that it has initiated Phase 3 safety and efficacy studies of Gevokizumab, which is an antibody used to treat diabetes and inflammatory disorders.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) close up on the day, after an upbeat survey for Eylea prompted RW Baird to raise its price target from $150 to $175 early Thursday. The company has increased its estimates prior to its third quarter results as well.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Humana Inc. (NYSE:HUM) announces that it has been chosen by the Kentucky Cabinet of Health and Family Services for participation in its comprehensive managed Medicaid program in Region 3, which serves Medicaid recipients who live in a 16-county region that incorporates Louisville, the state’s largest city.

Shares of the health-care data processor HMS Holdings Corp. (NASDAQ:HMSY) went over the cliff Thursday subsequent to the firm cutting its full-year guidance, explaining that it foresees lower-than-anticipated growth linked to its benefits-coordination unit, along with other delays.

Don’t Miss: Here’s Why NuVasive Came Crashing Down.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business